|
|
Adjuvant systems and vaccines
|
Three Studies Presented At 43rd EASL Showed Higher SVR For PEGASYS(R) (Peginterferon Alfa-2a) Plus Ribavirin T
|
Three Studies Presented at 43rd EASL Showed Higher SVR for PEGASYS(R) (Peginterferon Alfa-2a) Plus Ribavirin T
|
Roche's Investigational Hepatitis C Polymerase Inhibitor, R1626, Demonstrated Significant End-of-Treatment Res
|
Roche's Investigational Hepatitis C Polymerase Inhibitor, R1626, Demonstrated Significant End-of-Treatment Res
|
Roche's Investigational Hepatitis C Polymerase Inhibitor, R1626, Demonstrated Significant End-of-Treatment Res
|
Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing Hepatitis C
|
Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing Hepatitis C
|
COMMUNIQUE: PR Newswire: New Pegasys Data Show Hepatitis B Patients Achieve Highly Positive Treatment Response
|
New Pegasys Data Show Hepatitis B Patients Achieve Highly Positive Treatment
|
Roche's Investigational Hepatitis C Polymerase Inhibitor, R1626, Demonstrated Significant End-of-Treatment Res
|
Tenofovir shows excellent promise as a treatment for hepatitis B monoinfection
|
Gilead Announces 72-Week Data From Two Pivotal Phase III Studies Evaluating Viread(R) for the Treatment of Chr
|
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Stu
|
Chronic Care Focus: Hepatitis C: Silent, Deadly, Preventable
|
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatiti
|
Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatiti
|
High Growth Forecasted for the Vaccines 2008: World Market Analysis, Key Players, and Critical Trends in a Fas
|
TMC125 safety and tolerability in treatment-experienced hepatitis B or C coinfected patients in DUET-1 and DUE
|
